The risk and burden of thromboembolic and hemorrhagic events in patients with malignant gliomas receiving bevacizumab-Reference-Cited by-同舟云学术

The risk and burden of thromboembolic and hemorrhagic events in patients with malignant gliomas receiving bevacizumab

Published:2024-02-19 Issue:1 Volume:167 Page:181-188
ISSN:0167-594X
Container-title:Journal of Neuro-Oncology
language:en
Short-container-title:J Neurooncol

Author:

Dasgupta Pushan,Ou Alexander,Lin Heather,Gregory Timothy,Alfaro-Munoz Kristin D.,Yuan Ying,Afshar-Khargan Vahid,Kamiya-Matsuoka Carlos,Rousseau Justin F.,Majd Nazanin K.

Funder

National Institutes of Health/National Cancer Institute

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s11060-023-04551-9.pdf

Reference25 articles.

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005 Mar 10;352(10):987–96. doi: https://doi.org/10.1056/NEJMoa043330. PMID: 15758009.

2. Marras LC, Geerts WH, Perry JR (2000) The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer 89(3):640–646

3. Taal W, Oosterkamp HM, Walenkamp AM, Dubbink HJ, Beerepoot LV, Hanse MC, Buter J, Honkoop AH, Boerman D, de Vos FY, Dinjens WN, Enting RH, Taphoorn MJ, van den Berkmortel FW, Jansen RL, Brandsma D, Bromberg JE, van Heuvel I, Vernhout RM, van der Holt B … van den Bent MJ (2014) Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. The Lancet. Oncology, 15(9), 943–953. https://doi.org/10.1016/S1470-2045(14)70314-6

4. Chinot OL, de La Motte Rouge T, Moore N, Zeaiter A, Das A, Phillips H, Modrusan Z, Cloughesy T (2011) AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv Ther 28(4):334–340. https://doi.org/10.1007/s12325-011-0007-3

5. Simanek R, Vormittag R, Hassler M, Roessler K, Schwarz M, Zielinski C, Pabinger I, Marosi C. Venous thromboembolism and survival in patients with high-grade glioma. Neuro Oncol. 2007 Apr;9(2):89–95. doi: https://doi.org/10.1215/15228517-2006-035. Epub 2007 Feb 27. PMID: 17327573; PMCID: PMC1871666.